Oruka Therapeutics, Inc. • ORKA
Capital at risk.
About Oruka Therapeutics, Inc.
Ticker
Trading on
ISIN
Industry
Sector
CEO
Headquarters
Employees
Website
Metrics
Market cap
P/E ratio
EPS
Dividend Yield
Beta
Forward P/E ratio
EBIDTA
Ex dividend date
Price & volume
Market cap
Average daily volume
90-day return
30-day return
7-day return
Dividends
Dividend per share
Dividend yield
Forward dividend per share
Forward dividend yield
Payout ratio
Valuation
P/E ratio
Forward P/E
PEG ratio
Trailing P/E
Price to sales
Price to book
Earnings
EPS
EPS estimate (current quarter)
EPS estimate (next quarter)
EBITDA
Revenues (TTM)
Revenues per share (TTM)
Technicals
Beta
52-week High
52-week Low
50-day moving average
200-day moving average
Short ratio
Short %
Management effectiveness
ROE (TTM)
ROA (TTM)
Profit margin
Gross profit margin
Operating margin
Growth
Quarterly earnings growth (YoY)
Quarterly revenue growth (YoY)
Share stats
Outstanding Shares
Float
Insiders %
Institutions %
Analyst Insights & forecasts
100% Buy
0% Hold
0% Sell
Based on information from 8 analysts.
Average price target
Earnings per share (EPS) forecast
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.
Build your future fund today!
Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!
Capital at risk.
FAQs
Oruka Therapeutics, Inc. shares are currently traded for undefined per share.
Oruka Therapeutics, Inc. currently has 1M shares.
No, Oruka Therapeutics, Inc. doesn't pay dividends.
Oruka Therapeutics, Inc. 52 week high is $33.00.
Oruka Therapeutics, Inc. 52 week low is $5.49.
Oruka Therapeutics, Inc. 200-day moving average is $30.93.
The CEO of Oruka Therapeutics, Inc. is Dr. Lawrence Otto Klein Ph.D..
Oruka Therapeutics, Inc. has 28 employees.
The market cap of Oruka Therapeutics, Inc. is $888M.
The current P/E of Oruka Therapeutics, Inc. is null.
The EPS of Oruka Therapeutics, Inc. is $0.00.
The PEG Ratio of Oruka Therapeutics, Inc. is null.
According to the analysts Oruka Therapeutics, Inc. is considered a buy.